Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXingyu CaoYLYue LuDLDeyan Liu

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals CD3⁺ and CD34⁺ doses influence acute graft-versus-host disease in pediatric aplastic anemia patients undergoing cord blood transplant.

Key Points

  • Evaluate clinical outcomes of cord blood transplantation in pediatric patients with aplastic anemia.
  • Retrospective analysis of 63 pediatric patients with aplastic anemia undergoing cord blood transplantation.
  • Data collected from two hospitals in China from March 2013 to April 2024.
  • Endpoints included incidence of aGVHD and overall survival, with covariate analysis using Cox regression.
  • Grade II–IV aGVHD incidence by day 100 was 15.9%.
  • Five-year overall survival rate reached 83.6%.
  • Lower CD3⁺ cell dose significantly reduced the aGVHD risk (HR = 0.25).

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d408https://doi.org/10.1182/blood-2025-7752
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation2025
  2. 2Impact CD34+ cell doses and allograft composition on acute graft-versus-host disease: A single-center prospective cohort study2025
  3. 3High-dose individualized antithymocyte globulin with therapeutic drug monitoring in high-risk cord blood transplant2024 · 2 citations
  4. 4Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations
  5. 5Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025